Spring, TX, United States of America

Gowri Sukumar

This inventor holds 8 USPTO granted patents and 7 published patent applications. Top assignee: Iterion Therapeutics, Inc.. Active years: 2021-2025.

USPTO Granted Patents = 8 

% Patents Active = 100.0

Average Co-Inventor Count = 2.0

ph-index = 1

Forward Citations = 1(Granted Patents)


Company Filing History:


Years Active: 2021-2025

Loading Chart...
8 patents (USPTO):Explore Patents

Title: Gowri Sukumar: Innovator in Pharmaceutical Science

Introduction

Gowri Sukumar is a prominent inventor based in Spring, TX (US), known for her significant contributions to pharmaceutical science. With a total of seven patents to her name, she has made remarkable strides in the field of drug formulation and development.

Latest Patents

Among her latest patents is the invention of a crystalline form of tegavivint, which includes methods of preparation and use. This invention relates to crystalline forms of (9E,10E)-2,7-bis((3,5-dimethylpiperidin-1-yl)sulfonyl)anthracene-9,10-dione dioxime, along with pharmaceutical compositions that comprise this crystalline form. Additionally, she has developed lyophilized formulations of tegavivint, which include methods for making such formulations and methods for treating cancer by administering these formulations.

Career Highlights

Gowri Sukumar is currently associated with Iterion Therapeutics, Inc., where she continues to innovate and contribute to the advancement of pharmaceutical technologies. Her work focuses on developing effective treatments that can significantly impact patient care.

Collaborations

Gowri collaborates with various professionals in her field, including her coworker Drazen Ostovic, who brings valuable insights and expertise to their projects.

Conclusion

Gowri Sukumar's innovative work in pharmaceutical science, particularly her recent patents, showcases her dedication to improving healthcare solutions. Her contributions are paving the way for advancements in cancer treatment and drug formulation.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to [email protected]
Loading…